KRAS mutations exhibited no significant correlation with various clinicopathological factors, including patient age, gender, tumor location, growth pattern, Dukes’ stage, histological subtype, vascular invasion, or lymphocytic response, indicating that utilizing clinicopathologic features alone are not enough to interpret the nature of the tumor and patient outcomes. Here, KRAS is linked to neoplasm.